Method and apparatus for reducing tissue damage after ischemic injury
A technology of local ischemia and tissue, which is applied in the treatment of myocardial tissue injury and the field of acute ischemic syndrome, and can solve problems such as damage, side effects, and additional use
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0073] In this example, the drug delivery stent was filled with insulin in a manner substantially equivalent to the stent shown in Figures 2 and 3, which had an expanded area of approximately 3mm x 17mm. The stent is positioned on the mandrel, and an optional rapidly degrading layer is deposited in the opening of the stent. The rapidly degrading layer placed in the cavity is low molecular weight PLGA to protect subsequent layers during transport, storage and delivery. The layers described herein are deposited dropwise and delivered in liquid form by using a suitable organic solvent, such as DMSO, NMP or DMAc. Multiple layers of insulin and low molecular weight PLGA matrix are then deposited in the openings to form drug inlays for reducing ischemic damage. The insulin and polymer matrix are combined and deposited in such a way that about 70% of the total drug is released in the first about 2 hours, about 80% is released in about 8 hours, and in about 24 to 48 hours The aim ...
Embodiment 2
[0076] In this example, a drug delivery stent substantially equivalent to the stent shown in Figures 2 and 3, having an expanded area of about 3mm x 17mm, was loaded with a total dose of about 230 mg of insulin in the following manner. The stent is positioned on the mandrel, and an optional rapidly degrading layer is deposited in the opening of the stent. The rapidly degrading layer is PLGA. Layers of insulin and a poloxamer block copolymer of PEO and PPO (Pluronic F127) were then deposited in the openings to form a drug inlay for reducing ischemic damage. Insulin and polymer were combined in a ratio of approximately 33:67 and deposited in a manner similar to that described in Example 1 to achieve a drug delivery profile. A barrier layer of high molecular weight PLGA, a slowly degrading polymer, is deposited over the insulin layer to prevent insulin from migrating to the mural sides of the stent and the vessel wall. The rate of degradation of the barrier layer is selected ...
Embodiment 3
[0078] In this example, a drug delivery stent substantially equivalent to the stent shown in FIGS. , which has an expanded area of about 3 mm x 17 mm. The rate of degradation of the barrier layer is selected such that the cover layer does not begin to substantially degrade until after a dosing period of about 24 to 48 hours. The stent is positioned on the mandrel, and an optional rapidly degrading layer is deposited in the opening of the stent. The rapidly degrading layer is PLGA. Multiple layers of insulin and low molecular weight PLGA are then deposited in the openings to form a drug inlay for reducing ischemic damage. Insulin and polymer matrix were combined and deposited in a manner similar to that described in Example 1 to achieve a drug delivery profile. Multiple layers of high molecular weight PLGA (a slowly degrading polymer) and paclitaxel were deposited on top of the insulin layer to prevent paclitaxel delivery to the mural sides of the stent and the vessel wall...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More